About this item:

98 Views | 91 Downloads

Author Notes:

Correspondence and requests for materials should be addressed to V.H. (email: vahram.haroutunian@mssm.edu) or to E.S (email: eric.schadt@mssm.edu) or to B.Z. (email: bin.zhang@mssm.edu).

B.Z., E.S. and V.H. designed the study.

M.W. and N.B. performed data analyses.

V.H. and P.K. contributed to the patient consent, collection of samples.

V.H., P.K. and M.E. processed the samples.

M.W., N.B., V.H., E.S. and B.Z. wrote and edited the manuscript.

P.R., E.W., X.Z., Q.W., C.M., R.N., W.M., J.F.F., M.E.H., J.B., B.L., M.P., P.W., E.B.D., D.M.D., J.J.L. and N.T.S. contributed to the data analysis.

P.R., M.M., E.B.D., J.J.L., L.M., J.B., A.I.L., M.E. and S.G. discussed and contributed to writing.

All authors read and approved the manuscript.

No conflicts of interest declared.

Subjects:

Research Funding:

This work was supported by the grants R01AG046170, RF1AG054014, RF1AG057440 and R01AG057907 from the NIH/National Institute on Aging (NIA).

R01AG046170 is a component of the AMP-AD Target Discovery and Preclinical Validation Project.

Brain tissue collection and characterization was supported by NIH HHSN271201300031C.

Keywords:

  • Science & Technology
  • Multidisciplinary Sciences
  • Science & Technology - Other Topics
  • NETWORK ANALYSIS
  • EXPRESSION DATA
  • COEXPRESSION
  • ASSOCIATION
  • FRAMEWORK
  • VARIANTS
  • SEQUENCE
  • PROGRAM
  • TREM2
  • TOOL

The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease

Show all authors Show less authors

Tools:

Journal Title:

Scientific Data

Volume:

Volume 5

Publisher:

, Pages 180185-180185

Type of Work:

Article | Final Publisher PDF

Abstract:

Alzheimer’s disease (AD) affects half the US population over the age of 85 and is universally fatal following an average course of 10 years of progressive cognitive disability. Genetic and genome-wide association studies (GWAS) have identified about 33 risk factor genes for common, late-onset AD (LOAD), but these risk loci fail to account for the majority of affected cases and can neither provide clinically meaningful prediction of development of AD nor offer actionable mechanisms. This cohort study generated large-scale matched multi-Omics data in AD and control brains for exploring novel molecular underpinnings of AD. Specifically, we generated whole genome sequencing, whole exome sequencing, transcriptome sequencing and proteome profiling data from multiple regions of 364 postmortem control, mild cognitive impaired (MCI) and AD brains with rich clinical and pathophysiological data. All the data went through rigorous quality control. Both the raw and processed data are publicly available through the Synapse software platform.

Copyright information:

© The Author(s) 2018.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote